Brzostek D, Piotrowska B, Droszcz W
Kliniki Pneumonologii Akademii Medycznej, Warszawie.
Pneumonol Alergol Pol. 1994;62(7-8):352-7.
We studied 21 subjects with clinically stable atopic asthma. Our aim was to evaluate the relationship between the changes of the nonspecific bronchial responsiveness and spirometry, PEF- and laboratory parameters during 6 weeks observations. The spirometry values (FEV1%VC, MEF50), measurements of the provocative concentration of histamine causing a 20% fall in FEV1 (PC20H, according to Cockcroft) and analysis of blood eosinophil count and total IgE titre were performed twice, at 6 week interval. The studied patients recorded daily their symptoms and the number of puffs of betamimetics. They also measured daily their morning and evening PEF. We found any statistically significant changes during the study in evaluated parameters (t-Test). There was a degree of correlation between the symptom score and the use of bronchodilators. At the same time there were no trends in PC20H and the symptoms score, B2-agonist use, bronchial obstruction (FEV1%VC, MEF50) or mean amplitude of PEF. We conclude, that in the clinical assessment of asthma nonspecific bronchial responsiveness seems to be an independent variable.
我们研究了21名临床病情稳定的特应性哮喘患者。我们的目的是评估在6周观察期内非特异性支气管反应性变化与肺量计、呼气峰流速（PEF）及实验室参数之间的关系。肺量计值（第一秒用力呼气容积占肺活量百分比[FEV1%VC]、最大呼气中期流速[MEF50]）、使第一秒用力呼气容积下降20%的组胺激发浓度（PC20H，根据科克罗夫特法）的测量以及血嗜酸性粒细胞计数和总免疫球蛋白E滴度分析均每隔6周进行两次。研究中的患者每天记录其症状及β2受体激动剂的使用剂量。他们还每天测量早晚的呼气峰流速。我们在研究中未发现所评估参数有任何具有统计学意义的变化（t检验）。症状评分与支气管扩张剂的使用之间存在一定程度的相关性。同时，PC20H与症状评分、β2受体激动剂使用、支气管阻塞（FEV1%VC、MEF50）或呼气峰流速平均振幅之间均无变化趋势。我们得出结论，在哮喘的临床评估中，非特异性支气管反应性似乎是一个独立变量。
